The impact of CYP19A1 variants and haplotypes on breast cancer risk, clinicopathological features and prognosis
- PMID: 34014013
- PMCID: PMC8372086
- DOI: 10.1002/mgg3.1705
The impact of CYP19A1 variants and haplotypes on breast cancer risk, clinicopathological features and prognosis
Abstract
Background: Different genetic variants in hormone-regulating pathways have been identified to influence the risk of breast cancer. This study aimed to evaluate the association of CYP19A1 rs10046 and rs700519 polymorphisms with the risk, clinicopathological factors and prognosis of breast cancer.
Methods: In a case-control study, rs10046 and rs700519 polymorphisms were genotyped using ARMS-PCR and high-resolution melting (HRM), respectively, in a total of 702 females. Statistical analysis and evaluation of haplotypes and linkage disequilibrium were performed using SPSS v16, PHASE and 2LD.
Results: Although no association of rs700519 with breast cancer was observed, rs10046 in different genetic models as well as C-C/C-T and C-C/C-C diplotypes, revealed the association with the risk of breast cancer (p < 0.05). Moreover, the rs700519-C allele was shown to be associated with longer overall survival. In contrast, the T-T haplotype conferred s a shorter overall survival. rs700519-C allele was also significantly associated with menarche age.
Conclusion: Based on the identified independent association between CYP19A1 diplotypes and rs700519-C allele with the risk and prognosis of the disease, the gene region and its genetic variants may have a diagnostic and prognostic role in breast cancer development. Further confirmation using other variants in this locus can validate these findings.
Keywords: CYP19A1; rs10046; rs700519; biomarker; breast neoplasm; diagnosis; genetic variation; overall survival.
© 2021 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
Conflict of interest statement
No potential conflict of interest was reported by the authors.
Figures

Similar articles
-
Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.Breast Cancer Res Treat. 2020 Jul;182(1):147-158. doi: 10.1007/s10549-020-05656-9. Epub 2020 May 8. Breast Cancer Res Treat. 2020. PMID: 32385792
-
The CYP19A1 rs700519 Polymorphism and Breast Cancer Susceptibility in China: A Case-Control Study and Updated Meta-Analysis.Genet Test Mol Biomarkers. 2021 Jul;25(7):486-495. doi: 10.1089/gtmb.2021.0032. Genet Test Mol Biomarkers. 2021. PMID: 34280004
-
Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.Breast Cancer Res Treat. 2008 Nov;112(1):89-98. doi: 10.1007/s10549-007-9822-2. Epub 2007 Nov 30. Breast Cancer Res Treat. 2008. PMID: 18049890
-
Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.BMC Med. 2015 Jun 11;13:139. doi: 10.1186/s12916-015-0373-9. BMC Med. 2015. PMID: 26067721 Free PMC article.
-
Association between rs10046, rs1143704, rs767199, rs727479, rs1065778, rs1062033, rs1008805, and rs700519 polymorphisms in aromatase (CYP19A1) gene and Alzheimer's disease risk: a systematic review and meta-analysis involving 11,051 subjects.Neurol Sci. 2019 Dec;40(12):2515-2527. doi: 10.1007/s10072-019-04003-1. Epub 2019 Jul 5. Neurol Sci. 2019. PMID: 31278540
Cited by
-
Onco-immunity and therapeutic application of amygdalin: A review.J Oral Biol Craniofac Res. 2023 Mar-Apr;13(2):155-163. doi: 10.1016/j.jobcr.2022.12.010. Epub 2022 Dec 28. J Oral Biol Craniofac Res. 2023. PMID: 36618007 Free PMC article. Review.
-
In Vivo Growth Inhibition of Human Caucasian Prostate Adenocarcinoma in Nude Mice Induced by Amygdalin with Metabolic Enzyme Combinations.Biomed Res Int. 2022 May 21;2022:4767621. doi: 10.1155/2022/4767621. eCollection 2022. Biomed Res Int. 2022. Retraction in: Biomed Res Int. 2023 Jul 19;2023:9829041. doi: 10.1155/2023/9829041. PMID: 35637752 Free PMC article. Retracted.
-
Genetic architecture of mammographic density as a risk factor for breast cancer: a systematic review.Clin Transl Oncol. 2023 Jun;25(6):1729-1747. doi: 10.1007/s12094-022-03071-8. Epub 2023 Jan 13. Clin Transl Oncol. 2023. PMID: 36639603
References
-
- Bagherabad, M. B., Afzaljavan, F., Vahednia, E., Rivandi, M., Vakili, F., Sadr, S. S. H., Shandiz, F. H., & Pasdar, A. (2019). Association of Caspase 8 Promoter Variants and Haplotypes with the Risk of Breast Cancer and Its Molecular Profile in an Iranian Population: A case‐control Study. Journal of Cellular Biochemistry, 120(10), 16435–16444. 10.1002/jcb.28781 - DOI - PubMed
-
- Chace, C., Pang, D., Weng, C., Temkin, A., Lax, S., Silverman, W., Zigman, W., Ferin, M., Lee, J. H., Tycko, B., & Schupf, N. (2012). Variants in CYP17 and CYP19 cytochrome P450 genes are associated with onset of Alzheimer's disease in women with down syndrome. Journal of Alzheimer's Disease, 28(3), 601–612. 10.3233/jad-2011-110860 - DOI - PMC - PubMed
-
- Chattopadhyay, S., Siddiqui, S., Akhtar, M. S., Najm, M. Z., Deo, S. V., Shukla, N. K., & Husain, S. A. (2014). Genetic polymorphisms of ESR1, ESR2, CYP17A1, and CYP19A1 and the risk of breast cancer: A case control study from North India. Tumour Biology, 35(5), 4517–4527. 10.1007/s13277-013-1594-1 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical